黑石赚翻了

Core Viewpoint - Medline, a global healthcare company, has successfully gone public on NASDAQ, marking the largest IPO in the U.S. this year with a market capitalization exceeding $54 billion, providing substantial returns for its private equity backers [4][7][10]. Company Background - Medline was founded in 1966 by Jim and John Mills, inspired by their grandfather's sewing workshop in Chicago, initially focusing on manufacturing medical garments [8][9]. - The company briefly went public in 1972 but was privatized five years later, remaining a family-owned business until a private equity consortium acquired a majority stake in 2021 [9][13]. IPO Details - Medline's IPO raised approximately $6.26 billion by issuing 216 million shares at $29 each, with significant oversubscription, including cornerstone investments from entities like Singapore's GIC [10][12]. - The IPO not only surpassed the previous largest IPO of CATL in Hong Kong but also set a record for the largest private equity-backed IPO in history [10][13]. Financial Performance - Since the acquisition by private equity firms, Medline's revenue has surged nearly 50%, from $17.5 billion in 2020 to an estimated $25.5 billion in 2024 [13][14]. - The company has maintained a compound annual growth rate of 18% in sales since its inception, showcasing a remarkable growth trajectory [12]. Shareholder Gains - Major shareholders, including Blackstone, Carlyle Group, and Hellman & Friedman, collectively hold significant voting rights and have seen their investments appreciate substantially, with the value of Medline increasing by over $20 billion since the acquisition [15][16]. - Blackstone has already begun to realize profits from the IPO, selling approximately 13.46 million shares for about $382 million [15]. Future Outlook - Blackstone has several upcoming IPO projects, indicating a strong pipeline for future exits, with expectations of achieving one of its largest issuance years [16].